BioSpace News Archive

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today provides a full update on the savolitinib development programs in both lung cancer and kidney cancer.

INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that it has been granted Clinical Trial Authorization (CTA) by the United Kingdom (UK) regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA), for a Phase I clinical trial of its lead therapeutic candidate INKmune

Nevro Corp. today announced the company will be participating in the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of STELARA®

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI) as part of the annual re-ranking, which will become effective prior to market open on Monday, December 24, 2018.

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-AD clinical trial program evaluating the long-term safety and efficacy of ruxolitinib cream as monotherapy for adolescent and adult patients (age ≥ 12 years) with atopic dermatitis (AD) who are candidates for topical therapy.

President Trump Signs Bill Legalizing Low-THC Cannabis

Health Canada has released the results of its testing of sartan drugs in Canada.

The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the recent publication in Natureof favorable data from the phase 1 study GAPVAC-101, testing a novel therapeutic concept tailored to specific characteristics of patients’ individual tumors and immune systems

SAB Biotherapeutics, Inc. announced today, that it has raised $22 million in its Series A-2 round that closed December 15, 2018.